Epilepsy Patients Fight to Avoid SJS Side Effects

A number of anti-seizure medications are considered very safe by doctors and epilepsy specialists, an important consideration given that as many as half of all patients fail to continue their treatment. While Dilantin and Lamictal are known for links to a dangerous skin disorder, patients should also remain wary of Onfi Stevens-Johnson Syndrome (SJS) side effects.

The drug has only recently been approved by the U.S. Food & Drug Administration (FDA) and it is considered a second-line treatment for epilepsy patients who have not responded well to treatments. Like Dilantin and Lamictal, people who are dealing with seizures should be mindful of the risk of an autoimmune disorder that begins as a rash on the extremities and is accompanied by flu-like symptoms. 

However, there is no black-box warning regarding the potential for SJS side effects or, if the condition worsens, Toxic Epidermal Necrolysis, according to Onfi lawsuit lawyers. This lack of information for patients and doctors comes in spite of the fact that there are decades of data regarding the medication in other countries. Still, the major factor for these three drugs may be compliance by patients and the lack of efficacy of these treatments for some people dealing with seizures.

SJS occurs most often when people are either beginning a new drug regimen or when the dosage is titrated up or down. For patients who do not respond to Lamictal or Dilantin, there is additional risk each time they start one of these medications and that now includes Onfi Stevens-Johnson Syndrome side effects. For those who stop taking medications, similar concerns exist.

For many people looking to control their condition, it is important to consult with a doctor about the potential risks. Otherwise, it is important to watch out for any rashes or other signs of these skin disorders on a regular basis.

Many people, however, may not have been aware of the possibility of problems with these epilepsy treatments.